P1486: SERUM BIOMARKERS AS PREDICTORS OF RESPONSE TO SUTIMLIMAB IN COLD AGGLUTININ DISEASE (CAD): A POST-HOC ANALYSIS OF PHASE 3 CARDINAL AND CADENZA STUDY DATA

• Wilma Barcellini,
• Catherine M Broome,
• Bernd Jilma,
• Yasutaka Ueda,
• Josephine Vos,
• Shirley D’sa,
• Umer Khan,
• Ronnie Yoo,
• Marek Wardęcki,
• Alexander Röth

Affiliations

Wilma Barcellini

1 Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy

Catherine M Broome

2 MedStar Georgetown University Hospital, Division of Hematology, Washington, DC, United States

Bernd Jilma

3 Medical University of Vienna, Department of Clinical Pharmacology, Vienna, Austria

Yasutaka Ueda

4 Osaka University, Graduate School of Medicine, Osaka, Japan

Josephine Vos

5 Amsterdam UMC, University of Amsterdam and Sanquin, Amsterdam, The Netherlands

Shirley D’sa

6 University College London Hospitals NHS Foundation Trust, UCLH Centre for Waldenström’s Macroglobulinemia and Related Conditions, London, United Kingdom

Umer Khan

7 Sanofi, San Diego, CA, United States

Ronnie Yoo

8 Sanofi, Cambridge, MA, United States

Marek Wardęcki

9 Sanofi, Warsaw, Poland

Alexander Röth

10 University Hospital Essen, University of Duisburg-Essen, Department of Hematology and Stem Cell Transplantation, West German Cancer Center, Essen, Germany